Keywords: biogen, idec, ms, drugs, must, carefully, positioned

Biogen Idec's two MS drugs must be carefully positioned, say analysts

Article | 09 October 2006

Print This

US drugmaker Biogen Idec "must carefully position its two multiple sclerosis drugs Avonex [interferon beta-1a] and Tysabri [natalizumab], to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in